Cargando…
Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy
AIM: Use of immune checkpoint blockade to enhance T cell-mediated immunity within the hostile tumour microenvironment (TME) is an attractive approach in oesophageal adenocarcinoma (OAC). This study explored the effects of the hostile TME, including nutrient deprivation and hypoxia, on immune checkpo...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349772/ https://www.ncbi.nlm.nih.gov/pubmed/36445478 http://dx.doi.org/10.1007/s00432-022-04440-0 |
_version_ | 1785073991521665024 |
---|---|
author | Davern, Maria Donlon, Noel E. O’Connell, Fiona Gaughan, Caoimhe O’Donovan, Cillian McGrath, Jason Sheppard, Andrew D. Hayes, Conall King, Ross Temperley, Hugo MacLean, Michael Bulter, Christine Bhardwaj, Anshul Moore, Jenny Donohoe, Claire Ravi, Narayanasamy Conroy, Melissa J. Reynolds, John V. Lysaght, Joanne |
author_facet | Davern, Maria Donlon, Noel E. O’Connell, Fiona Gaughan, Caoimhe O’Donovan, Cillian McGrath, Jason Sheppard, Andrew D. Hayes, Conall King, Ross Temperley, Hugo MacLean, Michael Bulter, Christine Bhardwaj, Anshul Moore, Jenny Donohoe, Claire Ravi, Narayanasamy Conroy, Melissa J. Reynolds, John V. Lysaght, Joanne |
author_sort | Davern, Maria |
collection | PubMed |
description | AIM: Use of immune checkpoint blockade to enhance T cell-mediated immunity within the hostile tumour microenvironment (TME) is an attractive approach in oesophageal adenocarcinoma (OAC). This study explored the effects of the hostile TME, including nutrient deprivation and hypoxia, on immune checkpoint (IC) expression and T cell phenotypes, and the potential use of nivolumab to enhance T cell function under such conditions. METHODS AND RESULTS: ICs were upregulated on stromal immune cells within the tumour including PD-L2, CTLA-4 and TIGIT. OAC patient-derived PBMCs co-cultured with OE33 OAC cells upregulated LAG-3 and downregulated the co-stimulatory marker CD27 on T cells, highlighting the direct immunosuppressive effects of tumour cells on T cells. Hypoxia and nutrient deprivation altered the secretome of OAC patient-derived PBMCs, which induced upregulation of PD-L1 and PD-L2 on OE33 OAC cells thus enhancing an immune-resistant phenotype. Importantly, culturing OAC patient-derived PBMCs under dual hypoxia and glucose deprivation, reflective of the conditions within the hostile TME, upregulated an array of ICs on the surface of T cells including PD-1, CTLA-4, A2aR, PD-L1 and PD-L2 and decreased expression of IFN-γ by T cells. Addition of nivolumab under these hostile conditions decreased the production of pro-tumorigenic cytokine IL-10. CONCLUSION: Collectively, these findings highlight the immunosuppressive crosstalk between tumour cells and T cells within the OAC TME. The ability of nivolumab to suppress pro-tumorigenic T cell phenotypes within the hostile TME supports a rationale for the use of immune checkpoint blockade to promote anti-tumour immunity in OAC. GRAPHICAL ABSTRACT: Study schematic: (A) IC expression profiles were assessed on CD45(+) cells in peripheral whole blood and infiltrating tumour tissue from OAC patients in the treatment-naïve setting. (B) PBMCs were isolated from OAC patients and expanded ex vivo for 5 days using anti-CD3/28 + IL-2 T cell activation protocol and then co-cultured for 48 h with OE33 cells. T cell phenotypes were then assessed by flow cytometry. (C) PBMCs were isolated from OAC patients and expanded ex vivo for 5 days using anti-CD3/28 + IL-2 T cell activation protocol and then further cultured under conditions of nutrient deprivation or hypoxia for 48 h and T cell phenotypes were then assessed by flow cytometry. Key findings: (A) TIGIT, CTLA-4 and PD-L2 were upregulated on CD45(+) immune cells and CTLA-4 expression on CD45(+) cells correlated with a subsequent decreased response to neoadjuvant regimen. (B) Following a 48 h co-culture with OE33 cells, T cells upregulated LAG-3 and decreased CD27 co-stimulatory marker. (C) Nutrient deprivation and hypoxia upregulated a range of ICs on T cells and decreased IFN-γ production by T cells. Nivolumab decreased IL-10 production by T cells under nutrient deprivation-hypoxic conditions. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-022-04440-0. |
format | Online Article Text |
id | pubmed-10349772 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-103497722023-07-17 Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy Davern, Maria Donlon, Noel E. O’Connell, Fiona Gaughan, Caoimhe O’Donovan, Cillian McGrath, Jason Sheppard, Andrew D. Hayes, Conall King, Ross Temperley, Hugo MacLean, Michael Bulter, Christine Bhardwaj, Anshul Moore, Jenny Donohoe, Claire Ravi, Narayanasamy Conroy, Melissa J. Reynolds, John V. Lysaght, Joanne J Cancer Res Clin Oncol Research AIM: Use of immune checkpoint blockade to enhance T cell-mediated immunity within the hostile tumour microenvironment (TME) is an attractive approach in oesophageal adenocarcinoma (OAC). This study explored the effects of the hostile TME, including nutrient deprivation and hypoxia, on immune checkpoint (IC) expression and T cell phenotypes, and the potential use of nivolumab to enhance T cell function under such conditions. METHODS AND RESULTS: ICs were upregulated on stromal immune cells within the tumour including PD-L2, CTLA-4 and TIGIT. OAC patient-derived PBMCs co-cultured with OE33 OAC cells upregulated LAG-3 and downregulated the co-stimulatory marker CD27 on T cells, highlighting the direct immunosuppressive effects of tumour cells on T cells. Hypoxia and nutrient deprivation altered the secretome of OAC patient-derived PBMCs, which induced upregulation of PD-L1 and PD-L2 on OE33 OAC cells thus enhancing an immune-resistant phenotype. Importantly, culturing OAC patient-derived PBMCs under dual hypoxia and glucose deprivation, reflective of the conditions within the hostile TME, upregulated an array of ICs on the surface of T cells including PD-1, CTLA-4, A2aR, PD-L1 and PD-L2 and decreased expression of IFN-γ by T cells. Addition of nivolumab under these hostile conditions decreased the production of pro-tumorigenic cytokine IL-10. CONCLUSION: Collectively, these findings highlight the immunosuppressive crosstalk between tumour cells and T cells within the OAC TME. The ability of nivolumab to suppress pro-tumorigenic T cell phenotypes within the hostile TME supports a rationale for the use of immune checkpoint blockade to promote anti-tumour immunity in OAC. GRAPHICAL ABSTRACT: Study schematic: (A) IC expression profiles were assessed on CD45(+) cells in peripheral whole blood and infiltrating tumour tissue from OAC patients in the treatment-naïve setting. (B) PBMCs were isolated from OAC patients and expanded ex vivo for 5 days using anti-CD3/28 + IL-2 T cell activation protocol and then co-cultured for 48 h with OE33 cells. T cell phenotypes were then assessed by flow cytometry. (C) PBMCs were isolated from OAC patients and expanded ex vivo for 5 days using anti-CD3/28 + IL-2 T cell activation protocol and then further cultured under conditions of nutrient deprivation or hypoxia for 48 h and T cell phenotypes were then assessed by flow cytometry. Key findings: (A) TIGIT, CTLA-4 and PD-L2 were upregulated on CD45(+) immune cells and CTLA-4 expression on CD45(+) cells correlated with a subsequent decreased response to neoadjuvant regimen. (B) Following a 48 h co-culture with OE33 cells, T cells upregulated LAG-3 and decreased CD27 co-stimulatory marker. (C) Nutrient deprivation and hypoxia upregulated a range of ICs on T cells and decreased IFN-γ production by T cells. Nivolumab decreased IL-10 production by T cells under nutrient deprivation-hypoxic conditions. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00432-022-04440-0. Springer Berlin Heidelberg 2022-11-29 2023 /pmc/articles/PMC10349772/ /pubmed/36445478 http://dx.doi.org/10.1007/s00432-022-04440-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Davern, Maria Donlon, Noel E. O’Connell, Fiona Gaughan, Caoimhe O’Donovan, Cillian McGrath, Jason Sheppard, Andrew D. Hayes, Conall King, Ross Temperley, Hugo MacLean, Michael Bulter, Christine Bhardwaj, Anshul Moore, Jenny Donohoe, Claire Ravi, Narayanasamy Conroy, Melissa J. Reynolds, John V. Lysaght, Joanne Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy |
title | Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy |
title_full | Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy |
title_fullStr | Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy |
title_full_unstemmed | Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy |
title_short | Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy |
title_sort | nutrient deprivation and hypoxia alter t cell immune checkpoint expression: potential impact for immunotherapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349772/ https://www.ncbi.nlm.nih.gov/pubmed/36445478 http://dx.doi.org/10.1007/s00432-022-04440-0 |
work_keys_str_mv | AT davernmaria nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT donlonnoele nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT oconnellfiona nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT gaughancaoimhe nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT odonovancillian nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT mcgrathjason nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT sheppardandrewd nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT hayesconall nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT kingross nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT temperleyhugo nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT macleanmichael nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT bulterchristine nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT bhardwajanshul nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT moorejenny nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT donohoeclaire nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT ravinarayanasamy nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT conroymelissaj nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT reynoldsjohnv nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy AT lysaghtjoanne nutrientdeprivationandhypoxiaaltertcellimmunecheckpointexpressionpotentialimpactforimmunotherapy |